Overview

• Published October 6, 2025 in eNeuro (DOI: 10.1523/ENEURO.0114-25.2025), the Augusta University study tested cannabidiol delivered by inhalation in an established Alzheimer’s mouse model.
• Molecular and genetic assays showed reduced expression of key neuroinflammatory regulators with corresponding drops in proinflammatory molecules after treatment.
• The team reports modulation of innate-immune pathways involving IDO and cGAS, identifying distinct immune regulators affected by cannabidiol.
• Authors contend chronic autoinflammation contributes importantly to Alzheimer’s pathophysiology and propose cannabidiol as a potential multitarget candidate.
• Researchers stress the findings are limited to animals, with dosing, safety, reproducibility, and clinical relevance still to be determined before any therapeutic claims.